drugset / Trial / NCT00568516
Phase II Study of ASP3550 in Patients With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer
Timeline
- Start
- 2007-10
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | — | Subcutaneous |